Today: 23 April 2026
Ethereum near $1,950 as NFT “utility” pitch meets Polymarket’s $1.17 million price bet
20 February 2026
2 mins read

Ethereum near $1,950 as NFT “utility” pitch meets Polymarket’s $1.17 million price bet

SINGAPORE, Feb 20, 2026, 14:38 SGT

On Friday, Ether changed hands at $1,955.79, slipping 0.73% in the previous 24 hours. About $18.0 billion worth of Ether was traded, according to data from CoinMarketCap.

Ethereum’s narrative is once again in flux. This round, some investors are pointing to “utility” NFTs—think ticketing or licensing projects—as the main driver, instead of yet another hype cycle. Meyka, in a Feb. 19 note to UK clients, pegged ether at $1,963.24, down 1.39% for the day, highlighting that the relative strength index (RSI) was sitting close to 30, a mark plenty of traders see as oversold territory. The note also pointed to a wave of enterprise-grade NFT platforms now touting features like custody, fiat rails, KYC requirements and even dispute resolution. Meanwhile, project teams keep diversifying: Ethereum, layer-2 rollups, and competitors like Solana are all in play as efforts to shave down costs and hunt liquidity ramp up. Meyka

The back-and-forth spilled into Polymarket, with users putting down $1.17 million on a bet about ether’s price at noon ET on Feb. 19. The contract referenced Binance’s one-minute ETH/USDT close, according to the platform’s own rules. In the end, the market paid out “yes” for ether above $1,500 and $1,900, but not for levels above $2,000. Polymarket

Prediction markets are now facing criticism of their own. Ethereum co-founder Vitalik Buterin—who was among the early backers of Polymarket—flagged concerns on X, cautioning that the space could slide into “corposlop” fixated on “low-value gambling.” He specifically pointed to short-term bets on crypto prices, according to Business Insider. Business Insider

Macro risks are still front and center for major tokens. “No major catalyst looks set to push [cryptocurrencies] higher,” said Gerry O’Shea, head of market insights at Hashdex, in comments to Barron’s, highlighting lingering uncertainty over U.S. monetary policy and the broader economy. Bitcoin hovered around $67,088 as late U.S. trading wound down Thursday; ether edged up about 0.3%, per Dow Jones Market Data referenced by Barron’s. Barron’s

Utility isn’t just about NFTs, and plenty of it flies under the radar. Meyka, in a Feb. 11 note, highlighted things like enterprise pilots for luxury authentication, tokenized loyalty programs—think loyalty points as tokens—and Scope 3 emissions reporting, which tracks indirect emissions across a company’s value chain. According to the note, these applications generate steady, smaller on-chain transactions, which help drive both base fees and validator income—the payouts for network operators.

Ethereum keeps it simple: each transaction comes with a gas fee, usually settled in ether. Should transactions with steeper fees pick up and remain, validators pocket more, potentially lifting demand for the token that covers those costs.

The key question: which network gets the action. Layer-2s bundle up transactions, return them to Ethereum, which keeps user fees down. Solana, with its lower costs, is pushing to capture the rapid-fire, smaller trades—exactly the kind of volume that first gave NFTs their buzz.

The center of gravity doesn’t always stay put. Should “utility” end up as just another marketing tagline and liquidity start drying up, bids might vanish, price floors could plunge, and wash trading—fake deals that puff up volume—can scramble key trading signals.

Stock Market Today

  • ARS Pharmaceuticals (SPRY) Jumps 7.1% on FDA Nod and Strong Earnings Outlook
    April 23, 2026, 10:39 AM EDT. ARS Pharmaceuticals shares surged 7.1% to $8.40 on higher investor interest following FDA approval of expanded use for its lead product, neffy. The drop in minimum age restrictions allows its use in children and adults weighing at least 33 lbs for severe allergic reactions. The company anticipates a quarterly loss of 50 cents per share, improving 42.9% year-over-year, with revenues expected to increase 180.4% to $22.35 million. Earnings estimate revisions have been positive, with a 4.6% rise in the past month, often a signal of short-term price gains. ARS carries a Zacks Rank #3 (Hold). Aurinia Pharmaceuticals, a peer in the medical-drugs sector, also rose 3.8% recently amid improving earnings forecasts.

Latest article

Google Stock Gets Fresh AI Catalyst as Alphabet Unveils Agents, Chips Before Earnings

Google Stock Gets Fresh AI Catalyst as Alphabet Unveils Agents, Chips Before Earnings

23 April 2026
Alphabet Class A shares traded near $340 Thursday morning, valuing the company at about $4.1 trillion after Google unveiled new enterprise AI software and custom chips at its Cloud Next event. The announcements come days before Alphabet reports first-quarter earnings on April 29, with investors watching for signs that heavy AI and cloud spending will drive revenue growth.
FirstEnergy Ohio Rate Plan Could Add $4-$5 a Month to Bills as May 22 Filing Nears

FirstEnergy Ohio Rate Plan Could Add $4-$5 a Month to Bills as May 22 Filing Nears

23 April 2026
FirstEnergy’s Ohio utilities will file a three-year rate plan with state regulators by May 22, seeking to fund $800 million annually in grid upgrades and $83 million for tree trimming. The plan would raise monthly bills for typical 1,000-kWh households by $4.26 to $5.30 if approved. The filing follows recent rate cases by AES Ohio and AEP Ohio under the new House Bill 15 regime.
Salesforce stock slips as Momentum deal and UBS target cut put CRM in focus ahead of Feb. 25 earnings
Previous Story

Salesforce stock slips as Momentum deal and UBS target cut put CRM in focus ahead of Feb. 25 earnings

OCBC share price today: OCBC stock closes higher ahead of Feb 25 results
Next Story

OCBC share price today: OCBC stock closes higher ahead of Feb 25 results

Go toTop